Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [30]. Core Insights - The report highlights a 2.1% decline in the Shenwan Pharmaceutical and Biological Index, while the Shanghai Composite Index rose by 0.13% during the same period, ranking the pharmaceutical sector 28th among 31 sub-industries [3][4]. - The report emphasizes the anticipated large-scale production of brain-computer interface devices by Neuralink in 2026, predicting rapid development in the brain-computer interface sector and encouraging investment in related companies [3][13]. - Recent collaborations and advancements in drug development are noted, including a strategic partnership between Heptares Therapeutics and BlueNac to develop next-generation radionuclide drug conjugates, and the acceptance of clinical trial applications for innovative drugs by various companies [14][17]. - The report mentions significant licensing agreements, such as Zai Lab granting AbbVie exclusive rights to ZG006 outside Greater China, with potential payments reaching up to $1.235 billion [16]. - The report suggests investment opportunities in the CRO sector due to a recovering environment for innovative drugs, highlighting companies like Tigermed, Nanjing Legend, and others [3][24]. Market Performance - The pharmaceutical sector's overall valuation stands at 28.6 times earnings, ranking 10th among 31 Shenwan primary industries [7][24]. - The report details the performance of various sub-sectors within the pharmaceutical industry, with declines noted across multiple categories, including a 4.1% drop in offline pharmacies and a 2.6% drop in medical devices [4][7]. Recent Key Events - Neuralink's announcement regarding the mass production of brain-computer interface devices is expected to accelerate the development of the industry, supported by government policies aimed at fostering innovation [13]. - Heptares Therapeutics and BlueNac's collaboration aims to leverage advanced drug delivery systems to enhance treatment efficacy while minimizing damage to surrounding healthy tissues [14]. - The acceptance of clinical trial applications for innovative drugs, such as FB7013 targeting IgA nephropathy, indicates ongoing advancements in the pharmaceutical sector [17]. IPO Dynamics - New Tong Pharmaceutical's IPO application has been accepted, with a post-investment valuation of 3.81 billion yuan, focusing on significant liver disease treatments [18]. - Jingze Biopharmaceutical's IPO application has also been accepted, with a post-investment valuation of 3.18 billion yuan, specializing in reproductive and ophthalmic medications [21][22].

Group 1 - The company, HAPO Pharmaceuticals-B (02142), announced a share buyback plan, spending HKD 6.0134 million to repurchase 500,000 shares at a price range of HKD 11.78 to HKD 12.12 per share [1] - Additionally, the company issued 50,000 ordinary shares under the share incentive plan approved by shareholders on November 23, 2020, to fulfill share awards [1]

Group 1 - The company, Heber Pharmaceuticals-B (02142.HK), announced a share buyback plan on January 2, 2026, involving an expenditure of HKD 6.013 million to repurchase 500,000 shares [1] - The buyback price range is set between HKD 11.78 and HKD 12.12 per share [1]

Core Viewpoint - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan and issuance of shares for employee incentives [1] Group 1: Share Buyback - The company will repurchase 500,000 shares at a total cost of HKD 6.0134 million [1] - The buyback price per share ranges from HKD 11.78 to HKD 12.12 [1] Group 2: Share Issuance - The company will issue 50,000 ordinary shares to fulfill its share award plan approved by shareholders on November 23, 2020 [1]

呈交日期： 2026年1月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2026年1月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - The Hong Kong stock market experienced a strong upward trend in 2025, with the Hang Seng Index rising by 27.77% and the Hang Seng Tech Index increasing by 23.45%, driven by active trading and improved market sentiment [1][12]. Market Performance - The trading volume in the Hong Kong stock market significantly increased compared to previous years, indicating heightened trading activity and a broad release of market profit potential [1]. - The year saw a clear phase rotation in the market, with different sectors driving the market's upward movement at various times, including AI technology, innovative pharmaceuticals, and non-competitive policies leading to industrial optimization [3][5]. Sector Analysis - The technology sector was a major player in the market, with the Hang Seng Tech Index rising by 20.74% in Q1 2025, outperforming the Hang Seng Index's 15.25% increase during the same period [4]. - The innovative pharmaceutical sector gained momentum due to a surge in business development (BD) transactions, benefiting from improved global liquidity as the Federal Reserve began its rate-cutting cycle [4][5]. - The metals sector, particularly non-ferrous metals, emerged as the strongest performer by year-end, with copper stocks rising by 261.85%, gold and precious metals by 197.85%, and other metals and mining stocks by 187.91% [6][7]. Individual Stock Performance - Notable individual stock performances included Zijin Mining (02899.HK) rising by 162%, Shandong Gold (01787.HK) increasing by over 183%, and Jiangxi Copper (00358.HK) climbing nearly 281% [9]. - The stock of珠峰黄金 (01815.HK) skyrocketed by over 1286%, marking it as a rare "tenfold" stock in a year [9]. Investment Drivers - The rise in non-ferrous metals was attributed to multiple favorable factors, including the global trend of "de-dollarization," supply-demand imbalances in industrial metals, and domestic policies optimizing supply structures [6][10]. - The rapid development of emerging industries such as AI, new energy, and innovative pharmaceuticals provided a wealth of high-growth investment opportunities, supporting long-term stock price increases [12][13]. Future Outlook - Analysts expect the Hong Kong stock market to continue its upward trend in 2026, driven by improved liquidity and corporate profit recovery, with a potential shift in market driving logic from valuation recovery to profit growth [13].

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), announced the granting of 309,000 stock options to a qualified participant, which will take effect upon acceptance by the grantee [1] Group 1 - The stock options are part of a share option scheme adopted by the company's shareholders on November 23, 2020 [1]

Core Viewpoint - The company, HAPO (02142), announced the granting of 309,000 stock options to a qualified participant, which will take effect upon acceptance by the grantee [1] Group 1 - The stock options are part of a share option scheme adopted by the company's shareholders on November 23, 2020 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：02142） 授出購股權 本公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」） 第17.06A條刊發。 和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此宣佈，於2025年12月31日，根據本公司股東（「股東」）於2020年 11月23日採納的購股權計劃（「購股權計劃」），本公司向一名合資格參與者授出購 股權（「購股權」），惟須待該承授人接納後生效。 授出購股權 和鉑醫藥控股有限公司 HBM Holdings Limited 回補機制： 倘購股權計劃規則中訂明的以下事件發生，則任何尚 未行使的購股權將即時失效： 授出購股權均毋須經股東批准，且該購股權承授人並非本公司董事、主要行政人 員或主要股東（定義見上市規則）或上述任何人士的聯繫人（定義見上市規則）。 授出購股權（「授出購股權」）的詳情如下 ...